Take a trial of UK to unlock this pageFind out more
© Stockopedia 24th September, 2017

AstraZeneca

AZN 4912p 143.5  3.0%
22/09/17 0.500k

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 2 / 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2011 2012 2013 2014 2015 2016 TTM 2017E 2018E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 10th Aug, paid: 11th Sep more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ -8.2%

FINANCIAL BRIEF: For the six months ended 30 June 2017, AstraZeneca plc revenues decreased 11% to $10.46B. Net income increased 58% to $1.01B. Revenues reflect United States segment decrease of 28% to $3.01B, Western Europe segment decrease of 8% to $2.27B. Net income reflects Selling, General & Administrative Expens decrease of 12% to $3.73B (expense), Other operating income and expense increase from $468M to $958M (income). Dividend per share remained flat at $0.90. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
B+
B+
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 30th Jun '17) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2017
31st Dec 2018

Price Target: $65.5
(-1.21% below Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +5.3% ($) ($) ($) ($) ($) ($)
Consensus Estimate
1m Change
3m Change
34 brokers Broker Consensus Trend
Broker Recommendations for AstraZeneca
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 3 11 10 8

Named Brokers and Analysts
Bank of America Merrill Lynch Sachin Jain , Deutsche Bank Equity Research Richard Parkes , Cowen and Company , Jefferies Jeffrey Holford , HSBC Julie Mead , Credit Suisse Matthew Weston , Piper Jaffray Richard Purkiss , Morgan Stanley Nicolas Guyon-Gellin , Citi Andrew Baum, MD , SEB Equities Richard Koch , Leerink Partners LLC Seamus Fernandez , BERNSTEIN Tim Anderson , Investec Bank (UK) Plc Dr Andrew Whitney , Goldman Sachs Research Keyur Parekh , UBS Equities Alexandra Hauber , Danske Markets Lars Hevreng , Carnegie Investment Bank AB Erik Hultgard , Natixis Jean-Jacques Le Fur , Swedbank Markets Johan Unnerus , Exane BNP Paribas Simon Baker , Nordea Markets Michael Novod , Societe Generale Justin Smith , Handelsbanken Capital Markets Peter Sehested , Pareto Securities AS Peter Ostling , JPMorgan James Gordon , Berenberg Alistair Campbell , Oddo Securities Pierre Corby , Kepler Cheuvreux Mark Belsey , Barclays Emmanuel Papadakis , Shore Capital Stockbrokers Tara Raveendran , Bryan Garnier Eric Le Berrigaud , MainFirst Bank AG , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Liberum Naresh Chouhan , Alphavalue Kamla Singh , Cantor Fitzgerald Europe Brian White , Baader Helvea Equity Research Odile Rundquist , Beaufort Securities Ben Maitland , Foveal Amit Roy ,

Profile Summary

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Directors: Pascal Soriot (CEO) 57, Marc Dunoyer (CFO) 64, Fiona Cicconi (EVP) , Sean Bohen (EVP) , Pam Cheng (EVP) 45, Ruud Dobber (EVP) , Bahija Jallal (EVP) , Mark Mallon (EVP) , Menelas Pangalos (EVP) , Leon Wang (EVP) , Leif Johansson (NEC) 66, Philip Broadley (DRC) 53, Nazneen Rahman (NED) , Marcus Wallenberg (NED) 61, Genevieve Berger (NID) 62,

No. of Employees: 59,700 No. of Shareholders: 90,113


Last Annual December 31st, 2016
Last Interim June 30th, 2017
Incorporated June 17, 1992
Public Since September 21, 2007
Shares in Issue 1,265,897,109
Free Float 1.26bn (99.7%)

AZN Share Price Performance AZNQuote
4912p
143.5  3.0%
Traded 5:09pm · Minimum 15 min delayed · NMS: 0.500k

Latest AZN News Announcements (delayed)

Upcoming AZN Events
Friday 15th September, 2017
AstraZeneca PLC Roadshow - ASIA
Tuesday 26th September, 2017
AstraZeneca PLC at Goldman Sachs SRI Symposium
Wednesday 4th October, 2017
AstraZeneca PLC Roadshow - Dublin
Thursday 9th November, 2017
Q3 2017 AstraZeneca PLC Earnings Release
Friday 2nd February, 2018
Full Year 2017 AstraZeneca PLC Earnings Release

Recent ↓
Thursday 21st September, 2017
AstraZeneca PLC Roadshow - Holland & Brussels
Wednesday 13th September, 2017
AstraZeneca PLC Investor Science Event at ERS 2017
Tuesday 12th September, 2017
AstraZeneca PLC at Morgan Stanley Healthcare Conference
Sunday 10th September, 2017
AstraZeneca PLC Investor Science Event at ESMO 2017
Monday 14th August, 2017
AstraZeneca PLC Roadshow - Copenhagen
Monday 14th August, 2017
AstraZeneca PLC Roadshow - Helsinki
Monday 14th August, 2017
AstraZeneca PLC Roadshow - Oslo
Thursday 10th August, 2017
Dividend For AZN
Wednesday 9th August, 2017
Dividend For AZN
Wednesday 9th August, 2017
Dividend For AZN
Friday 4th August, 2017
AstraZeneca PLC Investor Roadshow - Geneva
Friday 4th August, 2017
AstraZeneca PLC Investor Roadshow - Toronto
Friday 4th August, 2017
AstraZeneca PLC Investor Roadshow - Zurich
Friday 4th August, 2017
AstraZeneca PLC Investor Roadshow - San Francisco
Thursday 3rd August, 2017
AstraZeneca PLC Investor Roadshow - Montreal
Thursday 3rd August, 2017
AstraZeneca PLC Investor Roadshow - Stockholm
Thursday 3rd August, 2017
AstraZeneca PLC Investor Roadshow - Los Angeles
Thursday 3rd August, 2017
AstraZeneca PLC Investor Roadshow - Frankfurt
Wednesday 2nd August, 2017
AstraZeneca PLC Investor Roadshow - Chicago
Wednesday 2nd August, 2017
AstraZeneca PLC Investor Roadshow - Edinburgh


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2017.


Should you buy AZN

Access AZN Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis